Pulsology rediscovered: Commentary on the Conduit Artery Function Evaluation (CAFE) study

Circulation

Volumn 113, Issue 9, 2006, Pages 1162-1163

  Oparil, Suzanne ^a,c   Izzo Jr , Joseph L ^b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Blood pressure; Editorials; Hypertension

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOSARTAN; PERINDOPRIL; THIAZIDE DIURETIC AGENT; VASOACTIVE AGENT;

AORTA PRESSURE; ARTERIAL PRESSURE; ARTERY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; EDITORIAL; HEART AFTERLOAD; HEART LEFT VENTRICLE HYPERTROPHY; HEMODYNAMICS; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; PULSE WAVE; SPHYGMOMANOMETRY; STROKE; TONOMETRY; BLOOD PRESSURE MEASUREMENT; INSTRUMENTATION; NOTE; PULSE RATE;

BLOOD PRESSURE DETERMINATION; HUMANS; HYPERTENSION; PULSE;

EID: 33645528752     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.609313     Document Type: Editorial

References (23)

1. The CAFE Investigators, for the Anglo-Scandinavian Cardiac Outcomes (ASCOT) Investigators. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213-1225.
2. Nichols WW, O'Rourke MF, eds. McDonald's Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles. London, UK: Hodder Arnold; 2005.
3. Society of Actuaries. Blood Pressure: Report of the Joint Committee on Mortality of the Association of Life Insurance Medical Directors and the Actuarial Society of America. New York, NY: Society of Actuaries; 1925.
4. Keith NM, Wagener HP, Barker NW. Some different types of essential hypertension: their course and prognosis. Am J Med Sci. 1939;197:132.
5. Kannel WB, Gordon T, Schwartz MJ. Systolic versus diastolic blood pressure and risk of coronary heart disease: the Framingham Study. Am J Cardiol. 1971;27:335-346.
6. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
7. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease: part 2, short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet. 1990;335:827-839.
8. Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet. 2000;356:1955-1964.
9. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358:1305-1315.
10. Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res. 2005;28:385-407.
11. Turnbull F, Neal B, Algert C; Blood Pressure Lowering Treatment Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet. 2003;362:1527-1535.
12. Dahlöf B, Devereux RB, Kjeldsen SE, for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995-1003.
13. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caufield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005;366:895-906.
14. Staessen JA, Birkenhager WH. Evidence that new antihypertensives are superior to older drugs. Lancet. 2005;366:869-870.
15. Poulter N, Wedel H, Dahlof B, Sever PS, Beevers DG, Caufield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, Pocock S, for the ASCOT Investigators. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet. 2005;366:907-913.
16. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens. 2004;17:118-123.
17. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41-46.
18. Izzo JL Jr. Arterial stiffness and the systolic hypertension syndrome. Curr Opin Cardiol. 2004;19:341-352.
19. Karamanoglu M, O'Rourke MF, Avolio AP, Kelly RP. An analysis of the relationship between central aortic and peripheral upper limb pressure waves in man. Eur Heart J. 1993;14:160-167.
20. Smulyan H, Siddiqui DS, Carlson RJ, London GM, Safar ME. Clinical utility of aortic pulses and pressures calculated from applanated radial-artery pulses. Hypertension. 2003;42:150-155.
21. Hope SA, Meredith IT, Cameron JD. Is there any advantage to using an arterial transfer function? Hypertension. 2003;42:e6-e7.
22. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004;364:1684-1689.
23. Lindholm LH, Carlberg B, Samuelsson O. Should β-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:1545-1553.